【レポートの概要（一部）】
1. Report Overview
1.1 Global Next-Generation Antibody Therapies Market Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Next-Generation Antibody Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Antibodies: An Overview
2.2.1 Monoclonal versus Polyclonal Antibodies
2.2.2 A Brief History of Antibody Drug Development
2.2.3 The Antibody Manufacturing Process
2.2.4 Trends in Antibody Development
2.3 Defining Next-Generation Antibodies
2.3.1 Classification of Next-Generation Antibody Therapies
2.3.2 The Need for Next-Generation Technologies
2.4 Development Trends for Next-Generation Antibodies
2.5 Phases of Clinical Trials
2.6 Scope of this Report
2.7 Currency Exchange Rates in This Report
3. Next-Generation Antibody Therapies: World Market 2015-2025
3.1 The World Next-Generation Antibody Therapies Market in 2014
3.1.1 Next-Generation Antibody Therapies Market Segmentation, 2014
3.1.2 Leading Next-Generation Antibody Therapies Products
3.2 World Next-Generation Antibody Therapies Market: Sales Forecast 2015-2025
3.3 How Will Segmental Market Shares Change to 2025?
3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2015-2025
4. Leading Regional Markets 2015-2025
4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market
4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2015-2025
4.3 How Will Regional Market Shares Change to 2025?
4.4 US Next-Generation Antibody Therapies Market 2015-2025
4.5 EU5 Next-Generation Antibody Therapies Market 2015-2025
4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2015-2025
4.7 Latin American Next-Generation Antibody Therapies Market 2015-2025
4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2015-2025
5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2015-2025
5.1 Antibody-Drug Conjugates: Market Overview, 2015
5.2 Leading ADCs in 2015
5.3 Antibody-Drug Conjugates: Market Forecast 2015-2025
5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2015-2025
5.4.1 Competition for Leading Drugs Will Restrain Growth in 2015-2025
5.4.2 Manufacturing ADCs Forms a Challenge
5.5 Adcetris (brentuximab vedotin, Seattle Genetics/Takeda)
5.5.1 Adcetris: Sales Forecast 2015-2025
5.5.2 Adcetris Meets Primary Endpoint in AETHERA Trial
5.5.3 Expanding Adcetris Indications for Future Revenue Growth
5.6 Kadcyla (trastuzumab emtansine, Roche)
5.6.1 Kadcyla: Sales Forecast 2015-2025
5.6.2 Phase 3 Results for Kadcyla/Perjeta Combination Disappoint
5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)
5.7.1 Mylotarg to be Relaunched?
5.8 Antibody-Drug Conjugate Platforms
5.8.1 Limited Market Opportunity for Radioconjugation
5.8.2 Seattle Genetics’ Platform Accounts for Over 50% of the Pipeline
5.8.3 ImmunoGen: TAP Technology
5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use
5.8.5 Preclinical Platforms for ADC Development
5.9 ADCs Are Attracting High-Value Deals
5.10 Antibody-Drug Conjugates: Pipeline Analysis 2015-2025
5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market
5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
5.11 Antibody-Drug Conjugates: Phase 3 Pipeline
5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)
5.11.2 Roche Attempts to Expand Kadcyla’s Breast Cancer Indication
5.11.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
5.11.2.2 RG7599/DNIB0600A (anti-NaPi2b) for Ovarian Cancer
5.11.2.3 RG7450/DSTP3086S (anti-STEAP1) for Prostate Cancer
5.12 Antibody-Drug Conjugates: Phase 2 Pipeline
5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
5.12.4 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)
5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
5.12.9 Seattle Genetics’ Phase 1 and Phase 2 ADCs
5.12.9.1 SGN-CD19A (anti-CD19) for DLBCL and ALL
5.12.9.2 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
5.12.9.3 SGN-CD33A: Using a New Cytotoxin and Linker Technology
5.12.9.4 SGN-CD70A (anti-CD70, Seattle Genetics)
5.13 Antibody-Drug Conjugates: Phase 1 Pipeline
5.13.1 Astellas Pharma: Partnered with Seattle Genetics for Phase 1 ADCs
5.13.2 Amgen’s AMG 595 (anti-EGFRv3) and AMG 172 (anti-CD27L)
5.13.3 Bayer’s Pipeline ADCs
5.13.3.1 Anetumab ravtansine (BAY 94-9343) (anti-mesothelin, Bayer)
5.13.3.2 C4.4a-ADC/BAY1129980 (anti-C4.4a, Bayer/Seattle Genetics)
5.13.3.3 FGFR2-ADC (anti-FGFR2, Bayer)
5.13.4 GSK2857916 (anti-BCMA, GSK/Seattle Genetics)
5.13.5 HuMax-TF-ADC (anti-TF, Genmab/Seattle Genetics)
5.13.6 ImmunoGen’s IMGN529 (anti-CD37), IMGN853 (anti-Folate receptor α) and IMGN289 (anti-EGFR)
5.13.7 LOP628 (anti-cKit, Novartis)
5.13.8 PF-06263507 (anti-5T4, Pfizer/Seattle Genetics)
5.13.9 Sanofi’s SAR408701 (anti-CEACAM5) and SAR566658 (anti-CA6)
5.13.10 SYD985 (trastuzumab duocarmycin; anti-HER2, Synthon)
5.14 Antibody-Drug Conjugates: Preclinical Pipeline
5.15 Future Developments in ADC Technology
5.15.1 Site-Specific Linkage for Improved Safety Profiles
6. Engineered Antibodies: Market Forecast and Pipeline 2015-2025
6.1 Engineered Antibodies: Market Overview, 2015
6.2 Leading Engineered Antibodies in 2015
6.3 Engineered Antibodies: Market Forecast 2015-2025
6.4 The Engineered Antibodies Market: Drivers and Restraints 2015-2025
6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
6.5.1 Poteligeo: Sales Forecast 2015-2025
6.6 Gazyva/Gazyvaro (obinutuzumab, Roche)
6.6.1 Gazyva as a Challenger in the anti-CD20 Market
6.6.2 Competition beyond Rituxan and Biosimilars
6.6.3 Gazyva: Sales Forecast 2015-2025
6.7 Engineered Antibodies Platforms
6.7.1 Roche Glycart: GlucoMAb – Glycosylation for Improved ADCC
6.7.2 Kyowa Hakko Kirin: Potelligent – Enhancing ADCC
6.7.3 Glycotope: GlycoExpress
6.7.4 MacroGenics: Fc Optimization
6.7.5 Xencor: XmAb – Modifying Amino Acids in the Fc Domain
6.7.6 Other Platforms for Increased Potency
6.8 Engineered Antibodies: Pipeline Analysis 2015-2025
6.9 Engineered Antibodies: Phase 3 Pipeline
6.9.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)
6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)
6.9.5 Ublituximab (anti-CD20, TG Therapeutics)
6.10 Engineered Antibodies: Phase 2 Pipeline
6.10.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
6.10.2 Margetuximab (anti-HER2, MacroGenics)
6.10.3 MEDI-551 (anti-CD19, AstraZeneca)
6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
6.10.5 Teplizumab (anti-CD3, MacroGenics)
6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
6.10.7 XmAb5871 (anti-CD19, Xencor)
6.11 Engineered Antibodies: Phase 1 Pipeline
6.11.1 Ocaratuzumab (anti-CD20, Mentrik Biotech)
6.11.2 RG7116 (anti-HER3, Roche)
6.11.3 MGA271 (MacroGenics/Servier)
7. Bispecific Antibodies: Market Forecast and Pipeline 2015-2025
7.1 Bispecific Antibodies: Market Overview, 2015
7.2 Bispecific Antibodies: Market Forecast 2015-2025
7.3 The Bispecific Antibodies Market: Drivers and Restraints 2015-2025
7.3.1 Manufacturing Bispecific Antibodies: Maintaining Stability and Purification
7.4 Removab (catumaxomab, Neopharm)
7.4.1 Removab: Sales Forecast 2015-2025
7.5 Blincyto (blinatumomab, Amgen)
7.5.1 Blincyto: Sales Forecast 2015-2025
7.6 Bispecific Antibodies Platforms
7.6.1 BiTE Platform: The Current Market Leader
7.6.2 MacroGenics’ DART Platform Holds Promise
7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2014-2024
7.6.4 Other Bispecific Antibody Platforms
7.6.4.1 DuoBodies (Genmab)
7.6.4.2 ImmTAC (Immunocore)
7.7 Bispecific Antibodies: Pipeline Analysis 2015-2025
7.8 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
7.8.1 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
7.8.2 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
7.8.3 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
7.8.4 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
7.8.5 SAR156597 (anti-IL-4 and IL-13, Sanofi)
7.8.6 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
7.9 Bispecific Antibodies: Phase 1 and Phase 1/2 Pipeline
7.9.1 COVA322 (anti-TNF and IL-17A, Johnson & Johnson)
7.9.2 IMCgp100 (anti-HLA-A2 and CD3, Immunocore)
7.9.3 Lymphomun (anti-CD20 and CD3, Trion Pharma/Fresenius Biotech)
7.9.4 MCLA-128 (anti-HER2 and HER3, Merus)
7.9.5 Rexomun (ertumaxomab) (anti-HER2 and CD3, Neopharm)
7.9.6 TF2 (anti-CEACAM5, Immunomedics)
7.9.7 AMG 211 (anti-CEA and CD3, Amgen/MedImmune)
7.9.8 BAY2010112 (MT112) (anti-PSMA and CD3, Bayer)
7.10 Bispecific Antibodies: Preclinical Pipeline
8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2015-2025
8.1 Antibody Fragments and ALPs: Market Overview, 2015
8.2 Antibody Fragments and ALPs: Market Forecast 2015-2025
8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2015-2025
8.4 Kalbitor (ecallantide, Dyax)
8.4.1 Kalbitor: Sales Forecast 2015-2025
8.5 Antibody Fragments and ALPs Platforms
8.5.1 Single-chain Variable Fragment Platforms
8.5.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
8.5.1.2 Nanobodies: The Smallest Antibody Fragment
8.5.1.3 Ablynx’s Nanobody Platform Has Created Many Clinical Candidates
8.5.1.4 Domain Antibodies: GSK and Crescendo Biologics
8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
8.5.2.1 DARPins: One-Tenth the Size of Antibodies
8.5.2.2 Anticalins (Pieris): Tested in Clinical Trials
8.5.2.3 Affibodies (Affibody)
8.5.2.4 Fynomers (Covagen/Johnson & Johnson)
8.5.2.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development?
8.5.2.6 Adnectins (Bristol-Myers Squibb)
8.5.2.7 AdAlta: i-bodies
8.5.3 Which Platform Will Lead the Market 2014-2024?
8.6 Antibody Fragments and ALPs: Pipeline Analysis 2015-2025
8.7 Antibody Fragments and ALPs: Phase 2 Pipeline
8.7.1 Ablynx Leads the Pipeline with Six Clinical Projects
8.7.1.1 Caplacizumab (anti-vWF)
8.7.1.2 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
8.7.1.3 Ozoralizumab (anti-TNFα)
8.7.1.4 ALX-0171 (anti-respiratory syncytial virus)
8.7.1.5 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
8.7.1.6 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
8.7.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
8.7.4 ESBA1008 (anti-VEGF, Novartis)
8.8 Antibody Fragments and ALPs: Phase 1 Pipeline
8.9 Antibody Fragments and ALPs: Preclinical Pipeline
9. Biosimilar Antibodies: Market Forecast 2015-2025
9.1 Biosimilar Antibodies: Market Overview, 2015
9.2 Leading Biosimilar Antibodies in 2015
9.3 Biosimilar Antibodies: Market Forecast 2015-2025
9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2015-2025
9.4.1.1 How Can Developers Ensure Uptake Among Physicians?
9.4.1.2 Automatic Substitution of Biosimilar Antibodies
9.4.1.3 Patent Expiries Will Hit Many Leading Antibodies in this Decade
9.4.1.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?
10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2015-2025
10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
10.1.1 Strengths
10.1.1.1 Approved Products Indicate a Path to Market Acceptance
10.1.2 Weaknesses
10.1.2.1 Challenges Exist With Current Monoclonal Antibody Therapies
10.1.3 Opportunities
10.1.3.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
10.1.4 Threats
10.1.4.1 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
10.2 STEP Analysis of the Next-Generation Antibody Therapies Market
10.2.1 Social Factors: Rising Demand for Cancer Therapies
10.2.1.1 Cancer Incidence Is Rising Rapidly
10.2.1.2 Next-Generation Antibodies for Personalised Medicine
10.2.2 Technological Developments Will Drive Pipeline Growth
10.2.2.1 There Are Many Competing Platforms
10.2.2.2 Manufacturing Challenges Exist for Most Sectors
10.2.2.3 New Analytical Tools for Target Identification and Protein Characterisation
10.2.3 Economic Pressures
10.2.3.1 Next-Generation Antibodies Are High-Cost
10.2.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
10.2.3.3 Next-Generation Launches for Product Lifecycle Management
10.2.4 Political and Regulatory Issues
10.2.4.1 Regulatory Challenges for Biosimilar Antibodies
10.3 Key Targets for Next-Generation Antibody Development 2015-2025
10.3.1 Oncology Is the Lead Indication in All Sectors
10.3.1.1 HER2 and HER3 for Breast Cancer
10.3.1.2 CD19 and CD20 for Lymphoma and Leukaemia
11. Research Interviews
11.1 Interview with Dr. Edwin Moses, CEO, Ablynx, Belgium
11.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
11.1.2 Manufacturing Nanobodies
11.1.3 Turning Challenges to Advantages
11.1.4 Nanobodies Are Further Developed than Other Antibody Scaffolds
11.1.5 The Commercial Potential for Nanobodies
11.1.6 Next-Generation Antibodies in China and Other Emerging Markets
11.2 Interview with Tim van Hauwermeiren, CEO, ArGEN-X, the Netherlands and Belgium
11.2.1 ArGEN-X’s Development Pipeline
11.2.2 Enhancing the Activity of ARGX-111
11.2.3 ArGEN-X’s SIMPLE Antibody™ Platform
11.2.4 Commercial Prospects for ArGEN-X’s Antibodies
11.2.5 Plans for Growth
11.2.6 Opportunities and Challenges for Next-Generation Antibody Developers
11.2.7 Therapeutic Areas for Manufacturers of Antibody Therapies
11.2.8 Other Trends and Developments in the Market
11.3 Interview with Mersana Therapeutics, Cambridge, Massachusetts, USA
11.3.1 Mersana’s Development Pipeline
11.3.2 Advantages of the Fleximer Platform
11.3.3 Future Plans for Mersana
11.3.4 The Outlook for ADCs in 2015-2025
12. Conclusions
12.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2015-2025
12.2 The World Next-Generation Antibody Therapies Market in 2014
12.2.1 Current Leading Next-Generation Antibody Therapies Segments
12.2.2 Leading Novel Next-Generation Antibody Therapies
12.2.3 Leading Regional Markets
12.3 World Next-Generation Antibody Therapies Market Forecast 2015-2025
12.4 Next-Generation Antibody Therapies: Late-Stage Pipeline
12.5 The Future of the Next-Generation Antibody Therapies Market?
12.5.1 A Strong Phase 1 and Phase 2 Pipeline
12.5.2 Technology Platforms Will Continue to Attract Big Pharma Interest
12.5.3 Most Developers Continue to Target Cancer
12.5.4 Strategies for Growth in 2015-2025
13. Glossary
【レポート販売概要】
■ タイトル：次世代抗体療法の世界市場：抗体薬物複合体（ADC）、エンジニアード抗体、二重特異性抗体、抗体断片/ALP、バイオシミラー抗体■ 英文：Next-Generation Antibody Therapies Market Forecast 2015-2025 : Opportunities for Leading Companies in ADCs, Engineered Antibodies, ALPs and Biosimilar Antibodies
■ 発行日：2015年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN5052606
■ 調査対象地域：グローバル
- 自動車用ベアリングの世界市場：玉軸受、ころ軸受The report covers the bearing market in terms of volume & value. The market size in terms of volume is provided from 2013 to 2020 in units, whereas the value of the market is provided in $million. The construction and mining equipment market is broadly classified by geography (Asia-Pacific, Europe, North America, and RoW), by vehicle type (PC, LCV, HCV & Two-Wheelers), by bearing type (Roller bear …
- 低圧/中圧開閉装置の世界市場2016-2020Technavio research analyst predicts the global LV and MV switchgear market to grow steadily at a CAGR of around 10% during the forecast period. Expansion and renovation of T&D projects globally are the primary growth drivers for this market. The growing demand for electricity has resulted in a manifold increase in the number of new T&D setups. Currently, the market is witnessing a shift from conve …
- 耐熱樹脂の世界市場予測（～2026）：種類別（エポキシ、シリコーン、アクリル、ポリエステル、 ポリエーテルスルホン、アルキド、ポリウレタン、フェノール類、ポリエーテルアミド）、用途別、地域別The global high temperature resin market is estimated to reach USD 4.88 Billion by 2026, at a CAGR of 4.44% from 2016 to 2026. The increasing demand for the high temperature resin as an alternative to mechanical fasteners in high end applications, growth in application areas, increasing demand for high temperature composite resins in railway and aerospace interior applications, and the increasing …
- Sexually-Transmitted Diseases in Japan 2014: Market Outlook and Emerging OpportunitiesAbout This ReportThis new 280-page report from Venture Planning Group presents detailed analysis of the Japanese STD market, including sales forecasts and supplier shares for Chancroid, Chlamydia, Gonorrhea, Herpes (I/II, VI), Papillomavirus (Pap Smear, HPV), and Syphilis. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition …
- 世界のビール市場：流通経路別、地域別Global Beer Market: About this market Technavio’s beer market analysis considers sales from both on-trade and off-trade distribution channels. Our study also finds the sales of beer in APAC, Europe, MEA, North America, and South America. In 2019, the on-trade segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as rising consumption …
- ダイアフラムポンプの世界市場：空気式ポンプ、電動式ポンプThe global diaphragm pumps market is projected to grow at a CAGR of 5.3% from 2016 to 2021 to reach USD 3.48 Billion by 2021. Development in water, wastewater, & sanitation sector and demand for diaphragm pumps from the chemical industry are the major factors driving the market. The report segments the diaphragm pumps market on the basis of its application in various end-user industries including …
- 世界の装甲車両・対IED防御車両市場動向2013-2023Why was the report written? “The Global Armored and Counter IED Vehicles Market 2013-2023” offers the reader detailed analysis of the global armored and counter IED vehicle market over the next ten years, alongside potential market opportunities to enter the industry, using detailed market size forecasts. What are the key drivers behind recent market changes? The global armored and counter IED veh …
- グルコース及びマルトデキストリンの世界市場：グルコースシロップ、デキストロース、マルトデキストリンToday, change in lifestyles of people across the world and the increasing urbanization demand for more processed and convenience foods. Processed foods use starch in sophisticated systems; this in turn is expected to fuel the demand for starch and its derivatives in the coming years. Starch derivatives such as glucose and maltodextrin are used in various food products, such as instant desserts, pr …
- グラフェンの世界市場：酸化グラフェン（GO）、グラフェンナノプレートレット（GNP）Graphene is the world’s first 2-D material, available in a thin layer of tightly packed carbon atoms bonded in a hexagonal honeycomb lattice. It is manufactured from graphite, through various processes such as exfoliation, epitaxial growth, and chemical vapor deposition (CVD), according to the application-specific requirement. It is also known as the “wonder material” owing to its exceptional prop …
- アメリカの産業用ロボット市場About Industrial Robotics Market in the US Industrial robots consist of a robotic arm, control cabinet, control panel, and other peripherals. They are used for various manufacturing applications, including welding, painting, pick and place, palletizing, cutting, assembly, and product testing, and inspection. They are often used to perform tasks that are repetitive, laborious, and dangerous. The in …
- マタニティウェアの世界市場2015-2019Global Maternity Wear: Market Analysis 2015-2019 Coverings: This report covers the growth prospects of the global maternity wear market in the power industry with segmentation based on types of apparel. Market shares for key geographies include EMEA, Americas, and APAC. It also includes an insightful analysis of the leading vendors of this market such as Amoralia, Destination Maternity, Envie De F …
- Gastric Cancer：グローバル臨床試験レビューH2, 2013Gastric Cancer Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Gastric Cancer Global Clinical Trials Review, H2, 2013" provides data on the Gastric Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastric Cancer. It includes an overview of the trial numbers and their recruitment status as per …
- 相互接続素子・受動素子の世界市場予測（～2022）：抵抗器、コンデンサ、誘導子、トランス、ダイオード、PCB、コネクタ、スイッチ、リレー、アダプター、ターミナル、スプライス、ソケットAccording to the MarketsandMarkets forecast, the interconnects and passive components market is expected to be valued at USD 187.55 Billion by 2022, growing at a CAGR of 4.41% between 2017 and 2022. The growth of the interconnects and passive components market is attributed to advancements in the industrial M2M communication technology and rising industrial automations, increasing demand for minia …
- 医療レポート：Acute Coronary Syndrome (ACS)-疫学予測（～2022）EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022 Summary Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly populatio …
- 石油・ガス陸上パイプラインの世界市場2016-2026Visiongain’s extensive and detailed 357 page report reveals that onshore oil and gas pipeline infrastructure will experience CAPEX of $68.7bn in 2016. If you are involved in the pipelines industry or intend to be, then you must read this report. It’s vital you keep your market knowledge up to date. Market scope: Oil & gas pipelines are an essential part of hydrocarbon transportation and distributi …
